Browsing tag:

chronic lymphocytic leukemia


Gilead Sciences has been granted marketing authorization by the European Commission for its Idelalisib 150mg tablets (to be marketed as Zydelig) to treat the two incurable blood cancers Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL). This formidable first-in-class oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, plays a key role in the activation, proliferation and[…]

Read More

Gilead has announced the July 23, 2014 Idelalisib FDA approved news. The Idelalisib (or the brand name Zydelig) approval was long awaited, to combat three forms of blood cancer. The FDA extended a nod to this powerful drug, which is estimated to earn roughly 1.2 billion dollars by the year 2020. Approved to treat three type[…]

Read More

Patients suffering from chronic lymphocytic leukemia {CLL} or small lymphocytic lymphoma {SLL} can breathe easier with the latest findings regarding Ibrutinib. Study results revealed at the beginning of June 2014 showed that the powerful anti-cancer drug Ibrutinib elicited a significant improvement for patients with either chronic lymphocytic leukemia or small lymphocytic lymphoma in both overall[…]

Read More

Idelalisib has captured the attention of pharmaceutical research and development teams with the latest data touting its targeted treatment for both unresectable non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The FDA accepted Gilead Sciences’ new drug application early in 2014 for the treatment of refractory indolent NHL, and the target review date for the[…]

Read More

The recent approval of Ofatumumab by the FDA is exciting news for the medical and pharmaceutical world. As a monoclonal antibody used to treat chronic lymphocytic leukemia, Ofatumumab garnished a Supplemental Biologic License Application in late April 2014. Known as the brand name drug Arzerra, which is marketed by both GlaxoSmithKline and Genmab this unique[…]

Read More

Exciting new was recently revealed from Pharmacyclics, when it was announced that the New Drug Application for Ibrutinib was placed on a priority basis by the FDA. This NDA for Ibrutinib is applicable in two different oncology indications. The first indication for Ibrutinib is for patients with mantle cell lymphoma (MCL) who have received prior[…]

Read More

The advent of the FDA Safety and Innovation Act of 2012 has led to an onslaught of new cancer treatments waiting to be approved. Now that the FDA can legally create a new status, known as a “breakthrough” designation, patients with life-threatening diseases such as cancer can obtain their medications faster and more efficiently. However,[…]

Read More

Ibrutinib was a shining star in the pharmaceutical headlines on June 20, 2013, with the news that this experimental drug used to treat chronic lymphocytic leukemia may be the next breakthrough cancer treatment. As a medication Ibrutinib is different from the usual chemotherapy treatments in that it pointedly targets specific processes, and prevents tumor proliferation.[…]

Read More